Microorganisms for treatment or prevention of corpulence and diabetes mellitus, and pharmaceutical composition containing the same

Abstract

The present invention relates to microorganisms for the treatment or the prevention of obesity or diabetes mellitus, which reduce the amount of monosaccharide or disaccharide which may be absorbed into human body by converting monosaccharides such as glucose, fructose, galactose et al. and disaccharides into polymeric materials which cannot be absorbed by the intestine, and relates to a pharmaceutical composition containing the said microorganisms.

What is claimed is:  
     
         1 . Lactobacillus sp. BC-Y009 (KCTC-0774BP).  
     
     
         2 . Acetobacter sp. BC-Y058 (KCTC-0773BP).  
     
     
         3 . A pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an amount effective to prevent or treat obesity and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         4 . The pharmaceutical composition according to  claim 3 , wherein said microorganism is selected from the group consisting of Acetobactor sp., Lactobacillus sp. and Lactococcus sp. bacteria.  
     
     
         5 . The pharmaceutical composition according to  claim 3 , wherein said microorganism is selected from the group consisting of  Acetobacter xylinum,  Acetobacter BC-Y058,  Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti,  Leuconostoc sp., Bacillus sp., Lactobacillus BC-Y009,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and Pediococcus sp.  
     
     
         6 . The pharmaceutical composition according to  claim 3 , wherein said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         7 . The pharmaceutical composition according to  claim 3 , which is a formulation suitable for oral administration.  
     
     
         8 . The pharmaceutical composition according to  claim 3 , which is a formulation coated with enteric coating materials.  
     
     
         9 . The pharmaceutical composition according to  claim 7 , which is a formulation coated with enteric coating materials.  
     
     
         10 . A pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an amount effective to prevent or treat diabetes mellitus and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         11 . The pharmaceutical composition according to  claim 10 , wherein said microorganism is selected from the group consisting of Acetobactor sp., Lactobacillus sp. and Lactococcus sp. bacteria.  
     
     
         12 . The pharmaceutical composition according to  claim 10 , wherein said microorganism is selected from the group consisting of  Acetobacter xylinum,  Acetobacter BC-Y058,  Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti,  Leuconostoc sp., Bacillus sp., Lactobacillus BC-Y009,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and Pediococcus sp.  
     
     
         13 . The pharmaceutical composition according to  claim 10 , wherein said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         14 . The pharmaceutical composition according to  claim 10 , which is a formulation suitable for oral administration.  
     
     
         15 . The pharmaceutical composition according to  claim 10 , which is a formulation coated with enteric coating materials.  
     
     
         16 . A method for preventing or treating obesity, comprising administering to a subject in need thereof a pharmacuetical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an amount effective to prevent or treat obesity and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         17 . The method according to  claim 16 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of Acetobactor sp., Lactobacillus sp. and Lactococcus sp. bacteria.  
     
     
         18 . The method according to  claim 16 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of  Acetobacter xylinum,  Acetobacter BC-Y058,  Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti,  Leuconostoc sp., Bacillus sp., Lactobacillus BC-Y009,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and Pediococcus sp.  
     
     
         19 . The method according to  claim 16 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         20 . The method according to  claim 16 , wherein the pharmaceutical composition is a formulation suitable for oral administration.  
     
     
         21 . The method according to  claim 16 , wherein the pharmaceutical composition is a formulation coated with enteric coating materials.  
     
     
         22 . The method according to  claim 20 , wherein the pharmaceutical composition is a formulation coated with enteric coating materials.  
     
     
         23 . A method for preventing or treating diabetes mellitus, comprising administering to a subject in need thereof a pharmacuetical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an amount effective to prevent or treat diabetes mellitus and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         24 . The method according to  claim 23 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of Acetobactor sp., Lactobacillus sp. and Lactococcus sp. bacteria.  
     
     
         25 . The method according to  claim 23 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of  Acetobacter xylinum,  Acetobacter BC-Y058,  Acetobacter hansenii, Acetobacter pasteurianus, Acetobacter aceti,  Leuconostoc sp., Bacillus sp., Lactobacillus BC-Y009,  Lactobacillus brevis, Lactobacillus helveticus, Lactobacillus bulgaricus, Lactobacillus casei, Lactobacillus kefir, Lactobacillus keriranofaciens, Lactobacillus bifidus, Lactobacillus sake, Lactobacillus reuteri, Lactobacillus lactis, Lactobacillus delbrueckii, Lactobacillus helveticusglucos  var.  jugurti., Lactococcus cremoris, Bifidobacterium bifidium, Streptococcus thermophilus  and Pediococcus sp.  
     
     
         26 . The method according to  claim 23 , wherein the pharmaceutical composition comprises at least one microorganism selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         27 . The method according to  claim 23 , wherein the pharmaceutical composition is a formulation suitable for oral administration.  
     
     
         28 . The method according to  claim 23 , wherein the pharmaceutical composition is a formulation coated with enteric coating materials.  
     
     
         29 . A method for controlling or preventing weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         30 . The method according to  claim 29 , wherein the said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         31 . The method according to  claim 29 , wherein the pharmaceutical composition is suitable for oral administration.  
     
     
         32 . The method according to  claim 29 , wherein the pharmaceutical composition is coated with enteric coating materials.  
     
     
         33 . A method for reducing weight gain, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         34 . The method according to  claim 33 , wherein the said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         35 . The method according to  claim 33 , wherein the pharmaceutical composition is suitable for oral administration.  
     
     
         36 . The method according to  claim 33 , wherein the pharmaceutical composition is coated with enteric coating materials.  
     
     
         37 . A method for controlling blood glucose level, comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         38 . The method according to  claim 37 , wherein the said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         39 . The method according to  claim 37 , wherein the pharmaceutical composition is suitable for oral administration.  
     
     
         40 . The method according to  claim 37 , wherein the pharmaceutical composition is coated with enteric coating materials.  
     
     
         41 . The method according to  claim 37 , wherein a normal blood glucose level is not affected.  
     
     
         42 . A method for controlling absorption of blood lipid, comprising comprising administering to a subject in need thereof a pharmaceutical composition comprising at least one microorganism selected from the group consisting of Acetobacter sp., Leuconostoc sp., Bacillus sp., Lactobacillus sp., Streptococcus sp., Bifidobacterium sp., Lactococcus sp. and Pediococcus sp. bacteria in an effective amount and a pharmaceutically acceptable carrier, wherein the microorganism is capable of producing polysaccharide.  
     
     
         43 . The method according to  claim 42 , wherein the said microorganism is selected from the group consisting of Acetobacter BC-Y058 and Lactobacillus BC-Y009.  
     
     
         44 . The method according to  claim 42 , wherein the pharmaceutical composition is suitable for oral administration.  
     
     
         45 . The method according to  claim 42 , wherein the pharmaceutical composition is coated with enteric coating materials.